Revelation Biosciences- Units (1 Ord share & 1 War) EBIT

Revelation Biosciences- Units (1 Ord share & 1 War) (REVBU) currently reports a EBIT of $-15B as of June 2026. That compares with $-8.1M in the prior-year period — down 182891.8% year over year. That is below the sector sector average of $-6.4M. Use the charts on this page to explore Revelation Biosciences- Units (1 Ord share & 1 War)'s EBIT history and peer comparisons.

Revelation Biosciences- Units (1 Ord share & 1 War)'s EBIT decreased from $-8.1M to $-15B — a 182891.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Revelation Biosciences- Units (1 Ord share & 1 War)'s EBIT of $-15B is lower than the its sector sector average of $-6.4M. That is roughly 232024.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Revelation Biosciences- Units (1 Ord share & 1 War) reported $-15B in EBIT as of June 2026. That compares with $-8.1M in the prior-year period — down 182891.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-15B, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-6.4M. From there, open related valuation or income-statement pages for Revelation Biosciences- Units (1 Ord share & 1 War), and consider following REVBU for alerts when major investors trade the stock.